Special Issue

Anticancer Agents: Design, Synthesis and Evaluation II

Message from the Guest Editor

The cancer-related mortality rate still remains high due to the various limitations of currently available therapies. The development of novel anticancer agents thus continues to be imperative to combat various deadly cancers. The emerging molecular targets and signal pathways enable the development of novel strategies to the rational design of new anticancer agents. Numerous well-established synthetic methods and biological screening assays pave the avenue for the discovery and development of new anticancer agents. The second edition of this Special Issue of *Molecules* continues to be devoted to all aspects of recent exploitation for new anticancer agents. Both original research and review articles, focusing on rational design, synthesis, and/or biological evaluation of various agents (including small molecules, natural products, endogenous molecules, antibodies and vaccines) as potential cancer therapeutics, are welcome to be submitted for publication in this Special Issue.

Guest Editor

Prof. Dr. Qiao-Hong Chen

Department of Chemistry and Biochemistry, California State University, Fresno 2555 E. San Ramon Ave. M/S SB70, Fresno, CA 93740, USA

Deadline for manuscript submissions

closed (30 September 2021)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/56147

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

